SUSPECT PULMONARY FIBROSIS
— a common threat across a wide range of ILDs, including connective tissue diseases (CTDs).1-3
Pulmonary fibrosis can become a key driver of irreversible harm and early mortality, and calls for urgent identification and intervention.4Find out more about the Risk
PROGRESSIVE FIBROSING ILD PHENOTYPE
See what Vincent Cottin, Professor of Respiratory Medicine, has to say about the threat of pulmonary fibrosis across a range of ILDs
THE IMPORTANCE OF HRCT SCANS ON BASELINE
See what Clive Kelly, Senior Lecturer, has to say about the prevalence of pulmonary fibrosis in patients with connective tissue diseases
CTD=connective tissue disease; HRCT=high-resolution computed tomography; ILD=interstitial lung disease
American Lung Association. Types, causes and risk factors of pulmonary fibrosis https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/pulmonary-fibrosis/introduction/types-causes-and-risk-factors.html. Accessed December 20, 2019.
Pulmonary Fibrosis Foundation. What is pulmonary fibrosis? https://www.pulmonaryfibrosis.org/life-with-pf/about-pf. Accessed December 20, 2019.
Fisher JH, et al. Baseline characteristics and comorbidities in the Canadian Registry for Pulmonary Fibrosis. BMC Pulm Med 2019;19:233.
American Lung Association. Pulmonary fibrosis progression and exacerbation. https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/pulmonary-fibrosis/patients/living-well-with-pulmonary-fibrosis/progression-and-exacerbation.html. Accessed December 20, 2019.
Cottin V, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018;27:180076.